A Phase 2 Open-Label Single-Arm Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy
Brief description of study
If you have been diagnosed with advanced or metastatic or surgically unresectable (cannot be removed) cholangiocarcinoma with an FGF2 translocation, you may qualify to participate in a clinical trial. The main goal of this phase II study is to evaluate the effectiveness of an experimental drug, INCB0548828 for the treatment of cholangiocarcinoma and what effects, good and/or bad, INCB054828 has on individuals with this type of cancer. In addition, we would like to evaluate the relationship between biomarkers (proteins) of interest.
Clinical Study Identifier: s16-02031
ClinicalTrials.gov Identifier: NCTs16-02031
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
